Christian Ramers
Internal Medicine · San Diego, CANPI 1730381385
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $413,672 of the $675,194 with a category attached, or 61.3%. Gilead accounts for 66.1% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $199,173 and has fallen 99.9% since, to $203 in 2025. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 898 payments — averaging $751.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$447K
- Viiv Healthcare Company$102K
- AbbVie$100K
- Beckman Coulter, Inc.$11K
- Merck$8K
- Pfizer$3K
- plus $4K from 6 others
What the payments were for
- Consulting fees$167,49025%
- Speaking & faculty fees$413,67261%
- Travel & lodging$74,26911%
- Food & beverage$19,7143%
- Education$480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 531 | $446,536 |
| Viiv Healthcare Company | 106 | $101,684 |
| AbbVie | 153 | $100,277 |
| Beckman Coulter, Inc. | 1 | $11,000 |
| Merck | 12 | $8,315 |
| Pfizer | 4 | $3,223 |
| Theratechnologies Inc. | 2 | $1,520 |
| GSK | 9 | $1,059 |
| Janssen Products, LP | 1 | $860 |
| Johnson & Johnson(2 entities) | 77 | $630 |
| Biocompatibles, Inc. | 1 | $68 |
| Indivior Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$675,194 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 127 | $495,656 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 23 | $83,968 |
| DovatoDolutegravir Sodium/Lamivudine | 28 | $78,717 |
| JulucaDolutegravir/Rilpivirine | 23 | $76,881 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 20 | $69,024 |
| PrezcobixDarunavir/Cobicistat | 28 | $65,204 |
| VemlidyTenofovir Alafenamide | 39 | $53,532 |
| PifeltroDoravirine | 18 | $29,437 |
| OzempicSemaglutide | 13 | $17,005 |
| LinzessLinaclotide | 12 | $6,168 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $5,893 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,906 |
| Testosterone | 17 | $990 |
| Gabapentin | 86 | $828 |
| Atorvastatin Calcium | 121 | $710 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Vemlidy | $446,536 | $633,156189 claims |
| Viiv Healthcare CompanyDovato, Juluca | $101,684 | $155,59851 claims |
| Johnson & JohnsonPrezcobix | $630 | $65,20428 claims |
| MerckPifeltro | $8,315 | $29,43718 claims |
| AbbVieLinzess | $100,277 | $6,16812 claims |
| GSKBreo Ellipta | $1,059 | $4,90612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in San Diego
- Hatim HusainSan Diego$2M
- Steven EdelmanSan Diego$863K
- Adam ZweigSan Diego$421K
- James BreitmeyerSan Diego$227K
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.